Evidence map›Paper›PMID 35879483›Full record

ReviewMikrochimica acta2022

Prussian blue: from advanced electrocatalyst to nanozymes defeating natural enzyme.

Maria A Komkova, Arkady A Karyakin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mikrochimica acta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maria A KomkovaChemistry Faculty of M.V. Lomonosov Moscow State University, 119991, Moscow, Russia.
Arkady A KaryakinChemistry Faculty of M.V. Lomonosov Moscow State University, 119991, Moscow, Russia. aak@analyt.chem.msu.ru.ORCID http://orcid.org/0000-0002-0457-7638

Funding

Russian Science Foundation 19-13-00131
6 · The paper itself

Abstract

The pathway from the advanced electrocatalyst to nanozymes defeating natural enzyme is reviewed. Prussian blue, being the most advantageous electrocatalyst for hydrogen peroxide reduction, is obviously the best candidate for mimicking peroxidase activity. Indeed, catalytically synthesized Prussian blue nanoparticles are characterized by the catalytic rate constants, which are significantly (up to 4 orders of magnitude) higher than for enzyme peroxidase. Displaying in addition the enzymatic specificity in terms of an absence of oxidase-like activity, catalytically synthesized Prussian blue nanoparticles can be referred to as nanozymes. The latter provide the most versatile method for surface covering with the electrocatalyst, allowing to modify non-traditional materials like boron-doped diamond. For stabilization, Prussian blue core can be covered with nickel hexacyanoferrate shell; the resulting core-shell nanozymes still defeat natural enzyme in terms of activity. Discovering the catalytic pathway of nanozymes "artificial peroxidase" action, we have found the novel advantage of nanozymes over the corresponding biological catalysts: their dramatically (100 times) improved bimolecular rate constants.

Indexed as

NanoparticlesPeroxidaseCatalysisFerrocyanidesPeroxidasesferric ferrocyanideFerrocyanidesPeroxidasePeroxidases(Bio)sensorsCatalytic pathwayNanoparticleNanozymePeroxidaseRate constant

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.